FI120136B - Mycobacterium vaccae immuunijärjestelmän Th2-aktiivisuuden hillitsemiseksi - Google Patents

Mycobacterium vaccae immuunijärjestelmän Th2-aktiivisuuden hillitsemiseksi Download PDF

Info

Publication number
FI120136B
FI120136B FI991384A FI991384A FI120136B FI 120136 B FI120136 B FI 120136B FI 991384 A FI991384 A FI 991384A FI 991384 A FI991384 A FI 991384A FI 120136 B FI120136 B FI 120136B
Authority
FI
Finland
Prior art keywords
vaccae
ova
activity
mice
response
Prior art date
Application number
FI991384A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI991384A0 (fi
FI991384A (fi
Inventor
Graham Arthur William Rook
John Lawson Stanford
Alimuddin Ismail Zumla
Original Assignee
Stanford Rook Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9626215.9A external-priority patent/GB9626215D0/en
Priority claimed from GBGB9626859.4A external-priority patent/GB9626859D0/en
Application filed by Stanford Rook Ltd filed Critical Stanford Rook Ltd
Publication of FI991384A0 publication Critical patent/FI991384A0/fi
Publication of FI991384A publication Critical patent/FI991384A/fi
Application granted granted Critical
Publication of FI120136B publication Critical patent/FI120136B/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
FI991384A 1996-12-18 1999-06-17 Mycobacterium vaccae immuunijärjestelmän Th2-aktiivisuuden hillitsemiseksi FI120136B (fi)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GBGB9626215.9A GB9626215D0 (en) 1996-12-18 1996-12-18 A therapeutic agent and its use
GB9626215 1996-12-18
GB9626859 1996-12-24
GBGB9626859.4A GB9626859D0 (en) 1996-12-24 1996-12-24 Medical treatment
GB9703460 1997-12-17
PCT/GB1997/003460 WO1998026790A1 (fr) 1996-12-18 1997-12-17 Mycobacterium vaccae destinee a la regulation negative de l'activite th2 du systeme immunitaire

Publications (3)

Publication Number Publication Date
FI991384A0 FI991384A0 (fi) 1999-06-17
FI991384A FI991384A (fi) 1999-06-17
FI120136B true FI120136B (fi) 2009-07-15

Family

ID=26310662

Family Applications (1)

Application Number Title Priority Date Filing Date
FI991384A FI120136B (fi) 1996-12-18 1999-06-17 Mycobacterium vaccae immuunijärjestelmän Th2-aktiivisuuden hillitsemiseksi

Country Status (18)

Country Link
EP (1) EP0951289B1 (fr)
JP (1) JP4358306B2 (fr)
KR (1) KR100533818B1 (fr)
CN (1) CN1129453C (fr)
AP (1) AP1044A (fr)
AT (1) ATE307600T1 (fr)
AU (1) AU730548B2 (fr)
BR (1) BR9713959A (fr)
CA (1) CA2273848C (fr)
DE (1) DE69734461T2 (fr)
DK (1) DK0951289T3 (fr)
ES (1) ES2251744T3 (fr)
FI (1) FI120136B (fr)
HK (1) HK1021316A1 (fr)
NO (1) NO321202B1 (fr)
NZ (1) NZ336147A (fr)
RU (1) RU2197989C2 (fr)
WO (1) WO1998026790A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6361776B1 (en) * 1999-12-06 2002-03-26 Genesis Research & Development Corp. Ltd. Compounds isolated from M. vaccae and their use in modulation of immune responses
US20030180260A1 (en) * 2000-06-19 2003-09-25 Clancy Robert Llewellyn Immunotherapy or treating bacterial or viral infection at mucosal surfaces with probiotics, and compositions therefor
AUPR101600A0 (en) * 2000-10-25 2000-11-16 Atheromastat Pty Ltd Compositions and methods for diagnosis and treatment of cardiovascular disorders
WO2002066055A1 (fr) * 2001-02-20 2002-08-29 Maruho Co., Ltd. Nouvelle utilisation en medecine d'un antigene alpha ou d'un gene d'antigene alpha
MX2017016931A (es) * 2015-06-24 2018-09-26 Immodulon Therapeutics Ltd Inhibidor del punto de regulacion y un mycobaterium de celula entera para uso en la terapia del cancer.
US11077179B2 (en) 2017-08-10 2021-08-03 Epicgenetics, Inc. Method for treating fibromyalgia and chronic fatigue syndrome

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL71683A0 (en) * 1984-04-27 1984-09-30 Yeda Res & Dev Pharmaceutical compositions for treating arthritis type diseases comprising fractions obtained from mycobacteria
GB9219425D0 (en) * 1992-09-14 1992-10-28 Univ London Therapeutic agent and its use
GB8919321D0 (en) * 1989-08-25 1989-10-11 Univ London Treatment of chronic inflammatory conditions
ATE154759T1 (de) * 1990-11-08 1997-07-15 Univ London Mycobacterium als adjuvans für antigene
GB9203814D0 (en) * 1992-02-21 1992-04-08 Univ London Treatment of long term auto-immune conditions
GB9406301D0 (en) * 1994-03-30 1994-05-25 Univ London Immunotherapeutic agent and its use
AUPM864894A0 (en) * 1994-10-07 1994-11-03 Borody, Thomas Julius Treatment of bowel-dependent neurological disorders

Also Published As

Publication number Publication date
AP9901553A0 (en) 1999-06-30
DK0951289T3 (da) 2006-03-13
FI991384A0 (fi) 1999-06-17
KR100533818B1 (ko) 2005-12-07
NO321202B1 (no) 2006-04-03
JP2001506256A (ja) 2001-05-15
DE69734461D1 (de) 2005-12-01
FI991384A (fi) 1999-06-17
WO1998026790A1 (fr) 1998-06-25
ATE307600T1 (de) 2005-11-15
AU7735598A (en) 1998-07-15
NO992957L (no) 1999-08-10
EP0951289A1 (fr) 1999-10-27
HK1021316A1 (en) 2000-06-09
CN1246056A (zh) 2000-03-01
JP4358306B2 (ja) 2009-11-04
NO992957D0 (no) 1999-06-17
EP0951289B1 (fr) 2005-10-26
ES2251744T3 (es) 2006-05-01
AP1044A (en) 2002-02-18
CN1129453C (zh) 2003-12-03
NZ336147A (en) 2001-03-30
CA2273848A1 (fr) 1998-06-25
DE69734461T2 (de) 2006-07-06
CA2273848C (fr) 2008-02-19
KR20000069518A (ko) 2000-11-25
AU730548B2 (en) 2001-03-08
RU2197989C2 (ru) 2003-02-10
BR9713959A (pt) 2000-04-11

Similar Documents

Publication Publication Date Title
US8512694B2 (en) Method of producing rough strains of bacteria and uses thereof
WO2001037865A1 (fr) Compositions et methodes pour le traitement des troubles allergiques
Agrawal et al. Flt3 ligand: a novel cytokine prevents allergic asthma in a mouse model
FI120136B (fi) Mycobacterium vaccae immuunijärjestelmän Th2-aktiivisuuden hillitsemiseksi
Burns et al. Immunology and infectious disease
Turner et al. In vitro investigations in asthmatic children undergoing hyposensitization with tyrosine‐adsorbed Dermatophagoides pteronyssinus antigen
US6878377B2 (en) Mycobacterium vaccae for down-regulation of the Th2 activity of the immune system
US6723327B1 (en) Methods and compounds for the treatment of immunologically-mediated diseases using mycobacterium vaccae
JP5523685B2 (ja) 使用
CN104411326A (zh) 抗哮喘的mtb-c疫苗
MXPA99005553A (en) Mycobacterium vaccae
Moore et al. Effect of antimacrophage serum on dermal tuberculin sensitivity and allergic pulmonary granuloma formation in rabbits
Burrows et al. Oral administration of PPC enhances antigen-specific CD8+ T cell responses while reducing IgE levels in sensitized mice
HU226255B1 (en) Mycobacterium vaccae for down-regulation of the th2 activity of the immune system
US20040247622A1 (en) Methods and compounds for the treatment of immunologically-mediated diseases using Mycobacterium vaccae
WO2002074330A2 (fr) Agent d'immunotherapie
KR101275227B1 (ko) 중증근무력증 예방, 개선 또는 치료용 조성물
WO2003006035A1 (fr) Compositions antivomitives
ALBERT et al. ALLERGY A CTS
AU1373401A (en) Compositions and methods for treatment of allergic disorders

Legal Events

Date Code Title Description
FG Patent granted

Ref document number: 120136

Country of ref document: FI

MM Patent lapsed